In Vitro Assessment of the Bioaccessibility and Hypoglycemic Properties of Essential Amino Acids Blend: Implication for Diabetes Management
Nutrients · 2025
DOI: 10.3390/nu17162606 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2025. Verfasst von Lorenza d'Adduzio und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Milan, Via Mangiagalli, 25, 20133 Milan, Italy. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Amino Acids, Essential, Hypoglycemic Agents, Dietary Supplements. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GUNA S.p.a.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background/Objectives: Essential amino acid (EAA) supplementation is often employed in sportive and clinical nutrition due to EAAs’ role in muscle mass maintenance and growth. EAAs are also involved in insulin and glucagone regulation in diabetes management, but only few reports investigate their possible implication as dipeptidyl peptidase-IV (DPP-IV) inhibitors and their effect on the stability and secretion of enteroendocrine hormones. A blend of EAAs (called GAF) available as a food supplement, in a specific qualitative and quantitative ratio, was investigated to address its in vitro bioaccessibility, its hypoglycemic properties in vitro and in situ on cellular models, and its safety on intestinal Caco-2 cells.
Methods
GAF was subjected to the INFOGEST static digestion protocol, producing the iGAF sample. iGAf DPP-IV inhibitory properties were investigated both in vitro and in situ on Caco-2 cells. Then, STC-1 enteroendocrine cells were employed alone and in co-culture with Caco-2 cells to evaluate iGAF’s impact on glucagon-like peptide 1 (GLP-1) hormone secretion.
Results
The study demonstrates that the present EAAs blend is stable and bioaccessible after simulated gastrointestinal digestion, and it is safe at the intestinal cellular level. It inhibits DPP-IV enzyme both in vitro and in situ and promotes GLP-1 secretion by enteroendocrine cells.
Conclusions
The sample demonstrated safety at the intestinal level and showed hypoglycemic properties by acting on a dual synergic mechanism that involves DPP-IV enzyme inhibition and GLP-1 hormone stimulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, University of Milan, Via Mangiagalli, 25, 20133 Milan, Italy.
- Department of Food, Nutrition and Environmental Sciences, University of Milan, Via Celoria, 2, 20133 Milan, Italy.
ORCID-Profile: Lorenza d'Adduzio, Melissa Fanzaga, Maria Silvia Musco, Marta Sindaco, Paolo D'Incecco, Giovanna Boschin, Carlotta Bollati, Carmen Lammi
Förderung
- GUNA S.p.a
Zitieren
APA
d'Adduzio, L., Fanzaga, M., Musco, M. S., Sindaco, M., D'Incecco, P., Boschin, G., Bollati, C., & Lammi, C. (2025). In Vitro Assessment of the Bioaccessibility and Hypoglycemic Properties of Essential Amino Acids Blend: Implication for Diabetes Management. Nutrients. https://doi.org/10.3390/nu17162606
Vancouver
d'Adduzio L, Fanzaga M, Musco MS, Sindaco M, D'Incecco P, Boschin G, et al. In Vitro Assessment of the Bioaccessibility and Hypoglycemic Properties of Essential Amino Acids Blend: Implication for Diabetes Management. Nutrients. 2025. doi:10.3390/nu17162606
BibTeX
@article{dAdduzio2025,
author = {d'Adduzio, Lorenza and Fanzaga, Melissa and Musco, Maria Silvia and Sindaco, Marta and D'Incecco, Paolo and Boschin, Giovanna and Bollati, Carlotta and Lammi, Carmen},
title = {In Vitro Assessment of the Bioaccessibility and Hypoglycemic Properties of Essential Amino Acids Blend: Implication for Diabetes Management},
journal = {Nutrients},
year = {2025},
doi = {10.3390/nu17162606}
}
EUVIMED